TaiRx, Inc. is a Taiwanese biotechnology company headquartered in Taipei, Taiwan, dedicated to developing novel therapeutics for cancer and neurodegenerative diseases. The company leverages its proprietary drug discovery platform to advance programs targeting unmet medical needs in Alzheimer's disease, Parkinson's disease, and oncology[1].
TaiRx represents an important player in Taiwan's growing biotechnology sector, combining local scientific expertise with international drug development standards. The company's focus on neurodegeneration addresses significant unmet needs in Asian populations where certain neurodegenerative diseases show distinct patterns.
| Attribute | Details |
|---|---|
| Headquarters | Taipei, Taiwan |
| Founded | 2010s (estimated) |
| CEO | Dr. John Lee |
| Focus Areas | Neurodegeneration, Oncology, Rare Diseases |
| Stock | Private |
| Funding | VC, Government grants, Strategic partnerships |
TaiRx was established in Taipei with a mission to develop innovative therapeutics for diseases with high unmet need. The company's founders recognized Taiwan's strengths in biomedical research and its potential to contribute to global drug development.
Since its founding, TaiRx has developed a pipeline of programs across therapeutic areas:
TaiRx has established collaborations with leading Taiwanese research institutions to support its drug discovery efforts.
TaiRx maintains a proprietary drug discovery platform[2]:
TaiRx has established:
TaiRx's lead neuroscience program targets mitochondrial dysfunction in neurodegeneration[3]:
| Attribute | Details |
|---|---|
| Mechanism | Novel neuroprotective agent targeting mitochondrial pathways |
| Target | Mitochondrial dysfunction in neurodegeneration |
| Stage | Preclinical development |
| Indication | Alzheimer's disease, Parkinson's disease |
Mitochondrial dysfunction is a central feature of neurodegenerative diseases:
TRX-101 aims to protect mitochondrial function, potentially slowing disease progression.
Alzheimer's disease program targeting toxic amyloid species[4]:
| Attribute | Details |
|---|---|
| Mechanism | Anti-amyloid aggregation |
| Target | Toxic Aβ oligomers |
| Stage | Lead optimization |
| Indication | Alzheimer's disease |
Amyloid-beta aggregation plays a central role in Alzheimer's disease pathogenesis:
Parkinson's disease candidate targeting protein aggregation:
| Attribute | Details |
|---|---|
| Mechanism | Alpha-synuclein modulation |
| Target | Protein aggregation pathways |
| Stage | Discovery |
| Indication | Parkinson's disease |
Alpha-synuclein aggregation is central to Parkinson's disease:
While the primary focus in NeuroWiki is on neurodegeneration, TaiRx also develops cancer therapeutics:
TaiRx collaborates with leading Taiwanese research institutions[5]:
TaiRx operates within Taiwan's growing biotechnology sector:
TaiRx competes in the neurodegenerative disease space:
TaiRx differentiates through:
TaiRx's future development includes:
TaiRx, Inc. Company Website. 2026. ↩︎
TaiRx. Research Programs. 2026. ↩︎